Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
head and neck cancer
Pharma
Keytruda's novel head and neck cancer nod comes with a limit
For the breakthrough perioperative head and neck cancer indication, Keytruda is only allowed in patients with PD-L1-positive tumors.
Angus Liu
Jun 13, 2025 10:50am
AACR: Keytruda delivers an industry first in head and neck cancer
Apr 28, 2025 1:28pm
Akeso’s Anniko enters crowded US PD-1 market
Apr 25, 2025 10:55am
Merck's Keytruda stages comeback in head and neck cancer
Oct 8, 2024 10:26am
Junshi, Coherus move Loqtorzi closer to another approval
Jun 12, 2024 11:45am
Coherus spurns 'heavily discounted' pricing for new PD-1 med
Oct 30, 2023 12:10pm
